Vitamin D receptor agonists to treat diseases involving CXCL12 activity

Patent metadata

Field	Value
Publication number	US-9895381-B2
Application number	US-201514959105-A
Country	US
Kind code	B2
Filing date	Dec 4, 2015
Priority date	Jun 5, 2013
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.

First claim

We claim:

1. A method of treating pancreatic ductal adenocarcinoma, comprising: administering to a mammalian subject having a pancreatic ductal adenocarcinoma a therapeutically effective amount of calcipotriol; and administering to the mammalian subject a therapeutically effective amount of gemcitabine, thereby reducing tumor volume and/or tumor growth, increasing intratumoral vasculature, and treating the pancreatic ducal adenocarcinoma in the subject.

2. The method of claim 1 , wherein the calcipotriol is administered prior to, or concurrently with, the gemcitabine.

3. The method of claim 1 , wherein administration of calcipotriol comprises oral, intraperitoneal, or intravenous administration of the calcipotriol.

4. The method of claim 1 , wherein the mammalian subject is a human subject.

5. The method of claim 1 , wherein administration of gemcitabine comprises oral, intraperitoneal, or intravenous administration of the gemcitabine.

6. The method of claim 1 , wherein administration of gemcitabine comprises intraperitoneal administration of the gemcitabine.

7. The method of claim 1 , wherein the calcipotriol is administered prior to the gemcitabine.

8. The method of claim 1 , wherein administration of calcipotriol comprises intraperitoneal administration of the calcipotriol.

Assignees

• Salk Inst For Biological Studi

Inventors

• Sherman Mara
• Downes Michael
• Evans Ronald M

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P5/48

  of the pancreatic hormones · CPC title

• A61P35/00

  Antineoplastic agents · CPC title